clinical success News
-
BenevolentAI To Present At The 40th Annual JP Morgan Healthcare Conference
London, 07 January, 2022BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that Joanna Shields, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January, 2022 at 8.00am ET / 13.00 GMT. About BenevolentAI BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the ...
By Benevolent
-
ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference
On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ICDS is held internationally every other year and is considered the premier conference for celiac disease. This year it will be held ...
-
Vilex Acquires DT MedTech and the Hintermann Series System Total Ankle Prostheses
Vilex, LLC, a member of the Squadron Capital family of businesses, announced today that it has successfully completed the acquisition of DT MedTech, LLC, whose product lines include the Hintermann Series System™ Total Ankle Replacement (TAR), developed by prominent surgeon, Professor Beat Hintermann. This exceptional TAR system includes the Hintermann Series H3 (H3) 3-piece, mobile-bearing ...
-
Empirical Spine Initiates PMA Submission Process for FDA Approval of Limiflex for Degenerative Spondylolisthesis
Empirical Spine, Inc., maker of the LimiFlex™ Paraspinous Tension Band, today announced initiation of the PMA process for FDA review and approval of the use of the LimiFlex with a decompression for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis. The Pivotal Trial supporting the PMA compares outcomes of patients who receive either LimiFlex or ...
-
Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) supplement for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. Cerapedics requested approval for an updated package insert that ...
-
FRONTBIO Inc IND Approval for Phase 1 Clinical Trial for Eczema Treatment
FRONTBIO, a new drug development bio company, announced on the 5th that it had received approval from the Ministry of Food and Drug Safety on the 2th of last month for a phase 1 clinical trial (IND) for 'FB1A1,' a new drug candidate material under development for the treatment of eczema. FB1A1 treats eczema by normalizing the hypersensitive immune response caused by the imbalance of cytokines ...
By Frontbio
-
How Great Clinical Trial Managers Stand Out From The Rest
Clinical Trial Manager roles are growing 32% faster than the national average. This job is undeniably rewarding but requires a high level of expertise and a knack for research. A clinical trial manager is responsible for many tasks, including overseeing everything from creating a valid test to its administration, recruitment, logistics, and follow-up. Hence, specific abilities ...
By Brio Group
-
Align Technology announces winner of 2020 Invisalign Ortho Summit Case Shoot-Out
Align Technology, Inc. (NASDAQ: ALGN) today announced the winner of the 2020 Invisalign Ortho Summit Case Shoot-out, one of the Company’s live case presentations during the virtual Summit. Dr. Keith Sellers of Charlotte, North Carolina received the greatest number of attendee votes for his Class II/Class III Invisalign case presentation. The Invisalign Ortho Summit Case Shoot-out program ...
-
NI Health Staff Recognised As Top Entrepreneurs
The Health Innovation Research Alliance Northern Ireland (HIRANI) are delighted to announce that seven innovative entrepreneurs from across Northern Ireland have been offered places on the NHS Clinical Entrepreneur Programme. Now in its 6th year and delivered by Anglia Ruskin University, the NHS Clinical Entrepreneur Programme had over 300 applications from staff across the NHS. Through a very ...
By TriMedika
-
Kardium® announces new financing to commercialize the Globe® System for the treatment of atrial fibrillation
VANCOUVER, B.C. – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, announced today that it has raised an undisclosed amount in a new financing round. The financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders. Kardium was ...
By Kardium Inc.
-
Empirical Spine Completes Investigational Arm Enrollment In Pivotal IDE Clinical Trial Studying LimiFlex In Degenerative Spondylolisthesis
Empirical Spine, Inc., maker of the LimiFlex Paraspinous Tension Band, today announced completion of enrollment in the investigational arm of its U.S. IDE trial studying the use of the LimiFlex with a decompression for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis. The trial compares outcomes of patients who receive either LimiFlex or transforaminal ...
-
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer ...
-
Kurve Therapeutics Announces Next-Gen Technology Designed for a New Approach to Treating CNS Disorders
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. Led by a team of experienced entrepreneurs with ...
-
NEC and OncoImmunity AS combine forces to use AI to empower personalized cancer immunotherapy
OncoImmunity AS today announced that it has been acquired by NEC Corporation, the renowned Japanese IT and network company, that recently launched its Artificial Intelligence (AI) driven drug discovery business. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity AS, founded in 2014, develops software that identifies neoantigen ...
-
VeriSIM Life Announces Acquisition of Molomics Biotech
VeriSIM Life (VeriSIM), the leading Artificial Intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced the acquisition of Molomics Biotech, a privately-held drug discovery company that leverages proprietary AI technology to design more efficacious and safer therapeutics to achieve higher successes in clinical trials. Founded in 2015 in ...
By VeriSIM Life
-
Centerline Biomedical Announces First-in-Human Use of IOPS™ Intra-Operative Positioning System
Centerline Biomedical, Inc., a spinout company from Cleveland Clinic, announced the successful first human clinical use of its groundbreaking IOPS™ technology. IOPS, the Intra-Operative Positioning System, provides doctors performing minimally-invasive vascular repairs with an intuitive, interactive color 3D display. Used in conjunction with standard 2D grayscale X-ray fluoroscopy ...
-
Empirical Spine Completes Enrollment in Pivotal IDE Clinical Trial Studying LimiFlex in Degenerative Spondylolisthesis
Empirical Spine, Inc., maker of the LimiFlex Paraspinous Tension Band, today announced completion of enrollment in its U.S. IDE trial studying the use of LimiFlex with a decompression for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis. The trial compares outcomes of patients who receive either LimiFlex or transforaminal lumbar interbody fusion (TLIF) ...
-
Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation
Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to ...
-
Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty
100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution clinical study at the international ...
By Robocath
-
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai. Clinical trials there and at three other centers are expected to begin this quarter. GTHP also ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you